News and Trends 16 Nov 2020
Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal
Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the…